Premium
Moderate Liver Impairment Has No Influence on Daptomycin Pharmacokinetics
Author(s) -
Dvorchik Barry
Publication year - 2004
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270004266619
Subject(s) - daptomycin , pharmacokinetics , medicine , lipopeptide , antibiotics , volunteer , staphylococcus aureus , adverse effect , gastroenterology , pharmacology , vancomycin , microbiology and biotechnology , bacteria , biology , agronomy , genetics
Daptomycin (N‐decanoyl‐L‐tryptophyl‐L‐asparaginyl‐L‐aspartyl‐L‐threonylglycyl‐L‐ornithyl‐L‐aspartyl‐D‐alanyl‐L‐aspartylglycyl‐D‐seryl‐threo‐3‐methyl‐L‐glutamyl‐3‐anthraniloyl‐L‐alanine‐lactone) is a novel cyclic lipopeptide antibiotic derived from the fermentation of Streptomyces roseosporus. Daptomycin was recently approved for the treatment of complicated skin and skin structure infections caused by aerobic gram‐positive bacteria, including those caused by methicillin‐resistant and methicillin‐susceptible Staphylococcus aureus. This single‐dose, parallel‐design, matchedcontrolled study was designed to evaluate the pharmacokinetics of daptomycin in subjects between ages 18 and 80 years with moderately impaired hepatic function (Child‐Pugh Class B, n = 10). Subjects were administered a single intravenous dose (6 mg/kg total body weight) over 30 minutes using a syringe pump. A normal volunteer control group matched by weight (±25 lb/11 kg), age (±10 years), and sex was included in this study for comparison to the hepatic‐impaired group. The pharmacokinetic parameters of daptomycin were similar in both groups. Adverse events occurred only in the hepatic‐impaired patients and were consistent with the subjects' disease state. In conclusion, subjects with moderate hepatic impairment receiving daptomycin do not require an adjustment in daptomycin dose or dose regimen.